Exercise Coaching for Heart Failure
Trial Summary
What is the purpose of this trial?
The goal of this study is to learn more about patients with heart failure with preserved ejection fraction (HFpEF) and exercise. Investigators want to see if meeting with a coach in person or by video conference will help these patients exercise, feel better, and change markers in their blood. Participants will be randomly placed in one of three groups for 18 months. All groups will have access to a fitness center and be given a watch and heart rate monitor to wear during exercise. The usual care group (control group) will have access to exercise videos via the medical fitness center and will not meet with a coach. The HEART Camp group will exercise and meet with their coach in-person at the medical fitness center. The HEART Camp Connect group will have access to exercise videos via the medical fitness center and will meet with their coach via videoconferencing. All participants will take part in an exercise test and study training prior to being randomized. At four data collection time points, participants will wear an activity monitor for 7 days each, have their blood drawn, and answer questions related to heart failure and exercise. Participants will also wear a heart rate monitor when they exercise and fill out a daily exercise diary.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should have stable medication therapy for the past 30 days, which suggests you may continue your current medications if they are stable.
What data supports the effectiveness of the treatment HEART Camp for heart failure?
Research shows that the HEART Camp exercise program helps people with heart failure stick to their exercise routines, which improves their physical function and quality of life. Exercise training, like that in HEART Camp, has been found to significantly enhance exercise capacity and some heart function indicators in patients with heart failure with preserved ejection fraction.12345
Is exercise coaching safe for people with heart failure?
What makes the HEART Camp treatment unique for heart failure with preserved ejection fraction?
HEART Camp is unique because it focuses on improving adherence to exercise through a multicomponent behavioral intervention, which is crucial for patients with heart failure with preserved ejection fraction (HFpEF) who often struggle to stick with exercise routines. This approach is different from other treatments as it combines exercise with strategies to change behavior, aiming to enhance long-term exercise commitment and improve patient outcomes.12389
Research Team
Windy W Alonso, PhD
Principal Investigator
University of Nebraska
Eligibility Criteria
This trial is for adults with a type of heart failure where the heart muscle pumps normally but is stiff (HFpEF). They must have been diagnosed via echocardiogram in the last 2 years, be on stable heart medication for at least a month, and meet certain criteria or show evidence of HFpEF.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Cardiopulmonary Exercise Testing (CPET) and Run-in Period
Participants undergo CPET to develop an exercise prescription and ensure safety, followed by a run-in period with 3 monitored sessions in cardiac rehabilitation and study orientation.
Intervention
Participants are randomized into one of three groups: HEART Camp, HEART Camp Connect, or Enhanced Usual Care. Intervention includes coaching sessions and exercise training.
Self-regulated Exercise
Participants are expected to self-regulate exercise without coaching support.
Follow-up
Participants are monitored for safety and effectiveness after the intervention period.
Treatment Details
Interventions
- HEART Camp
- HEART Camp Connect
HEART Camp is already approved in United States for the following indications:
- Heart failure with preserved ejection fraction (HFpEF)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Nebraska
Lead Sponsor